107O Mirvetuximab soravtansine (MIRV) plus carboplatin (Carbo) in folate receptor alpha (FRα)- positive platinum-sensitive ovarian cancer (PSOC): Outcomes by prior poly (ADP-ribose) polymerase inhibitor (PARPi)
In the phase II single-arm IMGN853-0420 trial, MIRV plus Carbo therapy in patients (pts) with FRα ≥25% recurrent PSOC demonstrated an objective response rate (ORR) of 68% and median PFS of 11 mo. In recurrent PSOC, prior PARPi exposure appears to diminish response to subsequent platinum-based rechallenge. Here we explored efficacy by prior PARPi subgroups.
Authors
- D. Roque
- P. Lim
- G.E. Konecny
- A.D. Santin
- R.N. Eskander
- P. Bessette
- S. Banerjee
- A.A. Secord
- D.M. Provencher
- J. Hong
- A. Madariaga Urrutia
- J. Sen
- E. Bako
- J.A. Perez Fidalgo
- S.L. Spunt
- A. Oaknin
- L. Gilbert
- U.A. Matulonis
- G. Lytle
Institutions
- Boston University (US)
- Northwestern University (US)
- Royal Marsden NHS Foundation Trust (GB)
- University of Nevada, Reno (US)
- Université de Sherbrooke (CA)
- McGill University Health Centre (CA)
- AbbVie (United States) (US)
- Yale University (US)
- University of California San Diego (US)
- Hospital Clínico Universitario de Valencia (ES)
- Los Angeles Medical Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Dana-Farber Cancer Institute (US)
- Centre Hospitalier de l’Université de Montréal (CA)
- Duke University Health System (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108154
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00